RHEOX
Device
Galvanize Therapeutics, Inc
Total Payments
$6.3M
Transactions
261
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.3M | 119 | 0 |
| 2023 | $2.8M | 107 | 1 |
| 2022 | $1.2M | 35 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.3M | 259 | 100.0% |
| Food and Beverage | $38.76 | 2 | 0.0% |
Payments by Type
Research
$6.3M
259 transactions
General
$38.76
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CS006 RheOx Pivotal | Galvanize Therapeutics, Inc | $3.9M | 0 |
| CS006 RHEOX PIVOTAL | Galvanize Therapeutics, Inc | $2.3M | 0 |
| CS003 US Early Feasibility Study | Galvanize Therapeutics, Inc | $36,031 | 0 |
| CS003 US EARLY FEASIBILITY STUDY | Galvanize Therapeutics, Inc | $12,746 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $6.3M
- Total Doctors 2
- Transactions 261
About RHEOX
RHEOX is a device associated with $6.3M in payments to 2 healthcare providers, recorded across 261 transactions in the CMS Open Payments database. The primary manufacturer is Galvanize Therapeutics, Inc.
Payment data is available from 2022 to 2024. In 2024, $2.3M was paid across 119 transactions to 0 doctors.
The most common payment nature for RHEOX is "Unspecified" ($6.3M, 100.0% of total).
RHEOX is associated with 4 research studies, including "CS006 RheOx Pivotal" ($3.9M).